Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MIMEDX GROUP, INC. (MDXG)

MiMedx Q2 net sales fall 35% to $64 million; agrees to acquire Sanara MedTech

Negative Impact 5 of 5 m&a Written later

MiMedx reported second-quarter 2026 net sales of $64 million, down 35% from $99 million a year earlier, and a net loss of $15 million versus net income of $10 million. The company reiterated its full-year 2026 net sales outlook of $260 million to $290 million and announced a definitive agreement to acquire Sanara MedTech for a total enterprise value of about $350 million, which shareholders will weigh against the company's weaker results.

Key points

  • Q2 net sales were $64 million versus $99 million a year earlier; Wound sales fell 61% while Surgical sales rose 15%.
  • Q2 net loss was $15 million compared with net income of $10 million in the prior-year quarter; gross margin was 69% versus 81%.
  • Sanara shareholders would receive $33.00 in cash and 0.4735 MiMedx shares per share, valued at $35 per share; the deal is funded partly by a $300 million term loan from Hayfin Capital Management.
  • The deal is expected to close by the end of 2026, subject to Sanara shareholder approval and regulatory approvals; 2026 net sales guidance of $260 million to $290 million was reiterated.

The filing

CompanyMIMEDX GROUP, INC. (MDXG)
Form8-K, current report
Filed with the SECJul 29, 2026, 4:08 PM ET
Accession number0001376339-26-000074

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.